Abstracts tagged "Biomarkers"

Abstract Number: 0248 • ACR Convergence 2022
Monocyte Chemoattractant Protein-1, Vascular Cell Adhesion Protein-1 and Asymmetric Dimethylarginine as Potential Biomarkers of Interstitial Lung Disease Associated with RA
Veronica Pulito-Cueto¹, Sara Remuzgo-Martinez¹, Fernanda Genre¹, Belén Atienza-Mateo¹, Víctor M. Mora-Cuesta¹, David Iturbe-Fernández¹, Leticia Lera-Gómez¹, Diana Prieto-Peña¹, Virgi Portilla¹, Ricardo Blanco², Alfonso Corrales¹, Oreste Gualillo³, José M. Cifrián¹, Raquel Lopez Mejias⁴ and Miguel Ángel González-Gay⁵, ¹Research Group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL; and Department of Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ²Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ³Hospital Clínico Universitario de Santiago, SERGAS (Servizo Galego de Saude) and IDIS (Instituto de Investigación Sanitaria de Santiago), NEIRID Lab (Neuroendocrine Interactions in Rheumatology and Inflammatory Diseases), Research Laboratory 9, Santiago de Compostela, Spain, ⁴IDIVAL, Santander, Spain, ⁵Department of Medicine and Psychiatry, Universidad de Cantabria; Rheumatology Division, Hospital Universitario Marqués de Valdecilla; Research group on genetic epidemiology and atherosclerosis in systemic diseases and in metabolic diseases of the musculoskeletal system, IDIVAL, Santander, Spain. Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
Background/Purpose: Interstitial lung disease (ILD) is one of the main comorbidities of patients with RA contributing to an increased mortality risk [1]. The pathogenesis of…
Abstract Number: 0491 • ACR Convergence 2022
Markers of Neutrophil Activation in Patients with ANCA-associated Vasculitis and Large-vessel Vasculitis
Despina Michailidou¹, Bhargavi Duvvuri¹, Runa Kuley¹, David Cuthbertson², Peter Grayson³, Nader Khalidi⁴, Curry Koening⁵, Carol Langford⁶, Carol McAlear⁷, Larry Moreland⁸, Christian Pagnoux⁹, Philip Seo¹⁰, Ulrich Specks¹¹, Antoine Sreih⁷, Kenneth J. Warrington¹¹, Tomas Mustelin¹, Paul Monach¹², Peter Merkel¹³ and Christian Lood¹, ¹Division of Rheumatology, University of Washington, Seattle, WA, ²University of South Florida, Tampa, FL, ³National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, ⁴Division of Rheumatology, Mc Master University, Ontario, Canada, Ontario, Canada, ⁵Division of Rheumatology, University of Utah, Salt Lake City, UT, USA, Salt Lake City, UT, ⁶Cleveland Clinic, Cleveland, OH, ⁷Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, USA, Philadelphia, PA, ⁸University of Colorado, Denver, CO, ⁹Division of Rheumatology, Mount Sinai Hospital, Toronto, ON, Canada, ¹⁰Johns Hopkins University, Baltimore, MD, ¹¹Mayo Clinic, Rochester, MN, ¹²VA Boston Healthcare System, Boston, MA, ¹³University of Pennsylvania, Philadelphia, PA
Background/Purpose: Neutrophils contribute to the pathogenesis of many autoimmune diseases. The purpose of the study was to assess two markers of neutrophil activation, calprotectin and…
Abstract Number: 0643 • ACR Convergence 2022
Subsetting SLE Patients Based on DNA Methylation at the Time of Disease Flare
Mary Horton¹, Joanne Nitithalm², Kimberly Taylor³, Laura Trupin⁴, Patricia Katz⁵, Jinoos Yazdany⁶, Maria Dall'Era⁷, Lisa Barcellos⁸, Lindsey Criswell⁹ and Cristina M Lanata¹⁰, ¹NIH/NHGRI, Oakland, CA, ²NIH/NHGRI, Bethesda, MD, ³University of Californi, San Francisco, San Francisco, CA, ⁴UC San Francisco, San Francisco, CA, ⁵UCSF, San Rafael, CA, ⁶UCSF, San Francisco, CA, ⁷University of California, Division of Rheumatology, San Francisco, CA, ⁸School of Public Health, UC Berkeley; National Human Genome Research Institute, National Institutes of Health, Berkeley, CA, ⁹National Human Genome Research Institute, NIH, Bethesda, MD, ¹⁰NIH/NHGRI, Washington, DC
Background/Purpose: Current treatments for SLE do not adequately prevent disease progression. This lack of efficacy, in part, relates to the molecular heterogeneity of disease. The…
Abstract Number: 0889 • ACR Convergence 2022
Serum Adipokines Predict Incident Osteoporotic Fracture in Patients with Rheumatoid Arthritis
Joshua Baker¹, Katherine Wysham², Bryant England³, Punyasha Roul⁴, Aleksander Lenert⁵, Grant Cannon⁶, Brian Sauer⁷, Geoffrey Thiele³ and Ted Mikuls⁸, ¹University of Pennsylvania, Philadelphia, PA, ²VA Puget Sound/University of Washington, Seattle, WA, ³University of Nebraska Medical Center, Omaha, NE, ⁴UNMC, Omaha, NE, ⁵University of Iowa, Iowa City, IA, ⁶Retired, Salt Lake City, UT, ⁷Salt Lake City VA/University of Utah, Salt Lake City, UT, ⁸Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Adipokines are fat and muscle-secreted protein hormones that regulate metabolism. Adiponectin has been associated with fracture in the general population while the role of…
Abstract Number: 1144 • ACR Convergence 2022
Circulating miRNAs and Difficult-To-Treat Rheumatoid Arthritis: The Screening Study
Jiří Baloun¹, Aneta Pekčcová², Heřman Mann³, Jiří Vencovský⁴, Karel Pavelka⁵ and Ladislav Šenolt⁴, ¹Institue of Rheumatology, Prague, Czech Republic, ²Institue of Rheumatology, Prague, Prague, Czech Republic, ³Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic, ⁴Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, ⁵Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, Praha, Czech Republic
Background/Purpose: Biologic (b-) and targeted synthetic (ts-) disease-modifying antirheumatic drugs (DMARDs) have brought significant progress in the treatment of rheumatoid arthritis (RA), but a significant…
Abstract Number: 1442 • ACR Convergence 2022
Role of Platelet-bound Complement Activation Product (PC4d) in Predicting Risk of Future Thrombotic Events in Systemic Lupus Erythematosus
Anca Askanase¹, John Conklin², Michelle Petri³, Vasileios Kyttaris⁴, Yevgeniya Gartshteyn⁵, Wei Tang¹, Anja Kammesheidt⁶ and Roberta Alexander², ¹Columbia University Medical Center, New York, NY, ²Exagen, Inc., Vista, CA, ³Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, MD, ⁴Beth Israel Deaconess Medical Center, Boston, MA, ⁵Columbia University Medical Center, Glen Rock, NJ, ⁶self, Laguna Beach, CA
Background/Purpose: Platelet-bound complement activation products (PC4d) are associated with a history of thrombosis in systemic lupus erythematosus (SLE) (Gartshteyn al., 2021; Petri et al., 2017).…
Abstract Number: 1607 • ACR Convergence 2022
Machine Learning Identifies Biomarker of Non-Response to Methotrexate in Rheumatoid Arthritis
Vincent Bouget¹, Julien Duquesne¹, Paul-Henry Cournède², Bruno Fautrel³, Francis Guillemin⁴, Pascal de Jong⁵, Judith Heutz⁶, Marloes Verstappen⁷, Annette van der Helm-van Mil⁸, Xavier Mariette⁹ and Samuel Bitoun¹⁰, ¹Scienta Lab, Paris, France, ²Paris-Saclay University - CentraleSupelec, Paris, France, ³Sorbonne University Paris, France and Pierre Louis Institute of Epidemiology and Public Health, Paris, France, Paris, France, ⁴Université de Lorraine, APEMAC, Vandoeuvre-les-nancy, France, ⁵ErasmusMC, Hendrik Ido Ambacht, Netherlands, ⁶Erasmus Medical Center, Rotterdam, Netherlands, ⁷Leiden University Medical Center, Leiden, Netherlands, ⁸Leiden University Medical Center, Erasmus Medical Center, Leiden, Netherlands, ⁹Paris-Saclay University, Rueil Malmaison, Ile-de-France, France, ¹⁰Paris-Saclay University, Paris, France
Background/Purpose: Methotrexate (MTX) is the first line treatment for rheumatoid arthritis (RA). Unfortunately, 30% to 40% of RA patients do not respond to MTX with…
Abstract Number: 1862 • ACR Convergence 2022
Lenabasum Reduces IFNγ and pIRF3 in Dermatomyositis Skin: Biomarker Results from a Double-Blind Phase 3 International Randomized Controlled Trial
Thomas Vazquez¹, Meena Sharma¹, Rui Feng², DeAnna Diaz³, Nilesh Kodali¹, Josh Dan³, Madison Grinnell³, Emily Keyes³, Grant Sprow³, Barbara White⁴ and Victoria Werth³, ¹Philadelphia VAMC, Philadelphia, PA, USA and Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ²University of Pennsylvania, Philadelphia, ³Philadelphia VAMC, Philadelphia, PA, USA and Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, ⁴Corbus Pharmaceuticals, Pleasanton, CA
Background/Purpose: Dermatomyositis (DM) is an autoimmune connective tissue disease that primarily affects the skin and lung; few effective treatment options are available. Lenabasum is a…
Abstract Number: 1993 • ACR Convergence 2022
Changes in Omega-6- and Omega-3-Derived Bioactive Lipids in Response to an Anti-Inflammatory Dietary Intervention
Esha Lal¹, Marta Sala Climent², francesca cedola², Marta Fernandez-Bustamante³, Meritxell Agustín-Perez², Maram Alharti², Abha Singh⁴, Soo-In Choi², Tania Rivera², Katherine Nguyen⁴, Susan Lee², Aaron Armando⁵, Tiffany Holt⁶, Oswald Quehenberger⁵, Shahrokh Golshan⁶, Roxana Coras⁷ and Monica Guma⁸, ¹Department of Medicine, School of Medicine, University of California, San Diego, San Diego, ²Department of Medicine, School of Medicine, University of California, San Diego, San Diego, CA, ³Department of Medicine, School of Medicine, University of California, San Diego, La Jolla, CA, ⁴University of California, San Diego, San Diego, CA, ⁵Department of Pharmacology, School of Medicine, University of California, San Diego, San Diego, CA, ⁶Department of Psychiatry, School of Medicine, University of California, San Diego, San Diego, CA, ⁷University of California San Diego, San Diego, CA, ⁸UCSD, La Jolla, CA
Background/Purpose: Rheumatoid arthritis (RA) is an autoimmune disease that causes joint pain, swelling, stiffness, and decreased mobility. Despite the various treatment options for RA, many…
Abstract Number: 2217 • ACR Convergence 2022
Disease Response in Rheumatoid Arthritis Across 4 Biologic Therapies Associates with Improvement in Paraoxonase-1 Activity
Amir Razmjou¹, Jennifer Wang¹, Ani Shahbazian¹, Jeffrey Curtis², Dimitrios Pappas³, Joel Kremer⁴ and Christina Charles-Schoeman⁵, ¹UCLA Medical Center, Los Angeles, CA, ²University of Alabama at Birmingham, Hoover, AL, ³CorEvitas, LLC, Waltham, MA, ⁴The Corrona Research Foundation, Delray Beach, FL, ⁵Division of Rheumatology, University of California, Los Angeles, Santa Monica, CA
Background/Purpose: Paraoxonase-1 (PON1) is a high-density lipoprotein (HDL)-associated enzyme with paraoxonase, lactonase, and arylesterase activities (1). PON1 is integral to the anti-inflammatory, anti-atherogenic functions of…
Abstract Number: 0251 • ACR Convergence 2022
Nuclear Factor of Activated T Cells Cytoplasmic 1 as a Potential Biomarker of Increased Cardiovascular Risk in Patients with Early Rheumatoid Arthritis
Sara Remuzgo-Martinez¹, Fernanda Genre¹, Veronica Pulito-Cueto², Alfonso Corrales¹, Virgi Portilla¹, Leticia Lera-Gómez¹, Belén Atienza-Mateo¹, María Sebastián Mora-Gil¹, J Gonzalo Ocejo-Vinyals³, Oreste Gualillo⁴, Ricardo Blanco⁵, Ivan Ferraz Amaro⁶, Santos Castañeda⁷, Raquel Lopez Mejias² and Miguel Ángel González-Gay⁸, ¹Research Group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL; and Department of Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ²IDIVAL, Santander, Spain, ³Department of Immunology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁴Hospital Clínico Universitario de Santiago, SERGAS (Servizo Galego de Saude) and IDIS (Instituto de Investigación Sanitaria de Santiago), NEIRID Lab (Neuroendocrine Interactions in Rheumatology and Inflammatory Diseases), Research Laboratory 9, Santiago de Compostela, Spain, ⁵Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ⁶Division of Rheumatology. Hospital Universitario de Canarias. Spain., Santa Cruz de Tenerife, Spain, ⁷Division of Rheumatology, Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Spain, ⁸Department of Medicine and Psychiatry, Universidad de Cantabria; Rheumatology Division, Hospital Universitario Marqués de Valdecilla; Research group on genetic epidemiology and atherosclerosis in systemic diseases and in metabolic diseases of the musculoskeletal system, IDIVAL, Santander, Spain. Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
Background/Purpose: NFKB1, NKIRAS1, NFATc1, NFATc2 and MTHFR, inflammation and immune response-related genes, predispose to the increased risk of cardiovascular (CV) disease in patients with RA…
Abstract Number: 0518 • ACR Convergence 2022
Changes in Skin Fibroblast Polarization Gene Expression Herald Clinical Improvement in Early, Diffuse Cutaneous Systemic Sclerosis
Kimberly Showalter Lakin¹, Deanna Jannat-Khah, DrPH, MSPH¹, Yajas Shah², Olivier Elemento², Aliza Bloostein¹, Jessica Gordon¹, Michael Whitfield³, Barbara White⁴, Dana Orange⁵ and Robert Spiera¹, ¹Hospital for Special Surgery, New York, NY, ²Weill Cornell Medicine, New York, NY, ³Dartmouth Geisel School of Medicine, Department of Biomedical Data Science, Lebanon, NH, ⁴Corbus Pharmaceuticals, Pleasanton, CA, ⁵The Rockefeller University, New York, NY
Background/Purpose: We previously identified a group of genes associated with high alpha-smooth muscle actin (aSMA) and low CD34 fibroblast staining in lesional systemic sclerosis (SSc)…
Abstract Number: 0648 • ACR Convergence 2022
Pathogenic Anti-C1q Antibodies Potentiate Activation of the Classical Complement Pathway in a Subset of Lupus Nephritis Patients
Edmund Chang¹, Julian Low², Ellen Cahir-McFarland², Henk-Andre Kroon², Yaisa Andrews-Zwilling², Ted Yednock² and Ann Mongan², ¹Annexon Biosciences, Brisbane, CA, ²Annexon Biosciences, South San Francisco, CA
Background/Purpose: In LN, excess immune complexes lead to nephrotic deposition of C1q and C4d, the latter of which has been correlated with circulating C4d and…
Abstract Number: 0892 • ACR Convergence 2022
Predicting Value of Circulating Semaphorin 4A for Rheumatoid Arthritis Progression and Response to Treatment
Jérôme Avouac¹, Eloïse Vandebeuque², Alice Combier³, lucile poiroux³, Alexia Steelandt³, Margaux Boisson³, Virginie Gonzalez⁴, Anne Cauvet⁴, Thomas Barnetche⁵, Marie Truchetet⁶, Christophe Richez⁷ and Yannick Allanore⁸, ¹University of Paris, Paris, France, ²hôpital Cochin, AP-HP AP-HP.Centre - Université Paris Cité, Paris, France, ³Hôpital Cochin, AP-HP.Centre - Université Paris Cité, Paris, France, ⁴INSERM U1016, Institut Cochin, Paris, France, ⁵CHU Bordeaux, Bordeaux, France, ⁶Bordeaux University Hospital, Bordeaux, France, ⁷Université de Bordeaux, Bordeaux, France, ⁸Department of Rheumatology A, Descartes University, APHP, Cochin Hospital, Paris, France, Paris, France
Background/Purpose: The lack of validated tools to predict rheumatoid arthritis (RA) disease course warrants the development of new reliable biomarkers. We have previously detected increased…
Abstract Number: 1149 • ACR Convergence 2022
A Novel Mitochondrial Variant as a Predictor for the Rapid Progressive Knee Osteoarthritis Phenotype: Development of a Predictive Model and Functional Studies
Alejandro Durán-Sotuela¹, Mercedes Fernández-Moreno¹, Tamara Hermida-Gómez¹, Sara Relaño¹, Victoria Suárez-Ulloa², vanesa Balboa-Barreiro³, Natividad Oreiro¹, Jorge Vázquez-García¹, FJ Blanco¹ and Ignacio Rego-Pérez¹, ¹Servicio de Reumatología. Instituto de Investigación Biomédica de A Coruña (INIBIC). Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas. Universidade da Coruña (UDC), A Coruña, Spain, ²Plataforma de Bioinformática. Instituto de Investigación Biomédica de A Coruña (INIBIC). Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas. Universidade da Coruña (UDC), A Coruña, Spain, ³Unidad de apoyo a la Investigación. Instituto de Investigación Biomédica de A Coruña (INIBIC). Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas. Universidade da Coruña (UDC), A Coruña, Spain
Background/Purpose: Knee osteoarthritis progression is heterogeneous in the population, being the most aggresive form the rapid progressive knee osteoarthritis (RPKOA). These patients suffer a worsening…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].